Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The Details: Block reported quarterly earnings of 62 cents per share, which missed the analyst consensus estimate of 68 cents ...

Opendoor Technologies is facing a pivotal moment as it battles a U.S. housing market that the CEO described as "very ...

Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Progressive activists in Hassan demand timely opening of super speciality hospital for improved health services.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Astera Labs soars 143% in Q2 2025, boosted by AI tech growth and key partnerships despite Russell index removal risk.

When it comes to compounded Ozempic and other semaglutides, Dr. Goulden adds that they are not identical to their ...